NASDAQ:GILD

Gilead Sciences Price Target, Predictions & Analyst Ratings

$71.33
-0.43 (-0.60 %)
(As of 09/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$70.81
$71.86
50-Day Range
$67.93
$73.03
52-Week Range
$56.56
$73.34
Volume5.31 million shs
Average Volume7.33 million shs
Market Capitalization$89.43 billion
P/E Ratio17.40
Dividend Yield3.96%
Beta0.39

Gilead Sciences (NASDAQ:GILD) Price Target and Consensus Rating

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analyst Rating Consensus

Buy
Based on 17 Analyst Ratings

Analyst Price Target Consensus

$109.88

High PT$625.00
Average PT$109.88
Low PT$61.00
TypeCurrent
9/16/20 to 9/16/21
1 Month Ago
8/17/20 to 8/17/21
3 Months Ago
6/18/20 to 6/18/21
1 Year Ago
9/17/19 to 9/16/20
Consensus Rating
Buy
Buy
Buy
Hold
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
10 Buy rating(s)
11 Buy rating(s)
11 Buy rating(s)
10 Buy rating(s)
Hold
7 Hold rating(s)
8 Hold rating(s)
9 Hold rating(s)
15 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
2 Sell rating(s)
Consensus Price Target$109.88$106.28$101.95$78.78
Price Target Upside54.04% Upside66.71% Upside62.02% Upside10.74% Upside
Get Gilead Sciences Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for GILD and its competitors with MarketBeat's FREE daily newsletter.


Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

Average Share Price and Price Target by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Gilead Sciences (NASDAQ:GILD) vs. Its Competitors

TypeGilead SciencesMedical CompaniesS&P 500
Consensus Rating Score
2.59
2.73
2.56
Consensus RatingBuyBuyBuy
Price Target Upside124.64% Upside7.43% Upside
News Sentiment RatingNeutral News
Neutral News
Neutral News
MarketBeat
Community Rating
Outperform Votes
2401
79.27%
Underperform Votes
628
20.73%
Avg. Outperform Votes
178
67.17%
Avg. Underperform Votes
87
32.83%
Avg. Outperform Votes
829
69.55%
Avg. Underperform Votes
363
30.45%

Gilead Sciences (NASDAQ:GILD) Analyst Ratings History

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
8/27/2021Morgan Stanley
Matthew Harrison
Reiterated RatingBuy$83.00+16.44%
8/23/2021Royal Bank of Canada
Brian Abrahams
Reiterated RatingBuyC$84.00+15.78%
7/30/2021SVB Leerink
Boost Price TargetOutperform$74.00 ➝ $77.00+10.27%
7/30/2021BMO Capital Markets
Boost Price TargetMarket Perform$67.00 ➝ $72.00+3.11%
6/28/2021Oppenheimer
Hartaj Singh
Initiated CoverageBuy$100.00+47.06%
5/7/2021Jefferies Financial Group
Michael Yee
Reiterated RatingBuy$80.00+19.49%
4/30/2021Needham & Company LLC
Reiterated RatingHold
4/1/2021Sanford C. Bernstein
UpgradeMarket Perform ➝ Outperform$80.00+23.78%
3/30/2021Redburn Partners
UpgradeNeutral ➝ Buy
2/5/2021Credit Suisse Group
Boost Price TargetNeutral$65.00 ➝ $66.00-1.40%
1/4/2021Guggenheim
UpgradeNeutral ➝ Buy
12/22/2020Smith Barney Citigroup
Lower Price Target$75.00 ➝ $72.00+25.90%
12/18/2020Truist Financial
Lower Price Target$67.00 ➝ $625.00+963.83%
12/16/2020Robert W. Baird
Brian Skorney
Boost Price TargetNeutral$63.00 ➝ $67.00+12.74%
12/15/2020Piper Sandler
Lower Price TargetOverweight$84.00 ➝ $80.00+34.61%
12/8/2020JPMorgan Chase & Co.
Reiterated RatingHold
10/29/2020Cantor Fitzgerald
Alethia Young
Reiterated RatingOverweight$84.00 ➝ $86.00+48.25%
10/29/2020Barclays
Lower Price Target$67.00 ➝ $62.00+6.93%
10/29/2020Wells Fargo & Company
Jim Birchenough
Lower Price TargetEqual Weight$69.00 ➝ $63.00+9.89%
10/28/2020UBS Group
Initiated CoverageNeutral$61.00+1.65%
9/15/2020Maxim Group
Jason McCarthy
UpgradeHold ➝ Buy$88.00+32.65%
9/14/2020Raymond James
Steven Seedhouse
Reiterated RatingHold
8/3/2020Citigroup
Boost Price Target$78.00 ➝ $80.00+11.28%
7/31/2020SunTrust Banks
Robyn Karnauskas
Boost Price TargetHold$73.00 ➝ $74.00+5.55%
6/15/2020DZ Bank
Elmar Kraus
Reiterated RatingBuy
5/13/2020Mizuho
Salim Syed
Reiterated RatingBuy$81.00+5.11%
4/29/2020Cfra
Boost Price TargetSell$71.00 ➝ $74.00-11.97%
4/13/2020Cowen
Josh Jennings
Reiterated RatingBuy$80.00+6.27%
3/31/2020Wolfe Research
Initiated CoverageMarket Perform$65.00-13.95%
3/2/2020HC Wainwright
DowngradeBuy ➝ Neutral
2/5/2020Bank of America
Boost Price TargetNeutral$70.00 ➝ $72.00+9.35%
5/28/2019The Goldman Sachs Group
DowngradeNeutral ➝ Sell$70.00 ➝ $60.00-10.30%
5/17/2019Evercore ISI
Umer Raffat
Reiterated RatingBuy
3/7/2019Piper Jaffray Companies
Tyler Van Buren
Set Price TargetHold$75.00+19.94%
1/3/2019CIBC
UpgradeMarket Perform ➝ Outperform$85.00+28.77%
(Data available from 9/16/2016 forward. View 10+ years of historical ratings with our analyst ratings screener.)
speech bubbles
speech bubbles











Gilead Sciences (NASDAQ:GILD) Analyst Ratings Frequently Asked Questions

What is Gilead Sciences's consensus rating and price target?

According to the issued ratings of 17 analysts in the last year, the consensus rating for Gilead Sciences stock is Buy based on the current 7 hold ratings and 10 buy ratings for GILD. The average twelve-month price target for Gilead Sciences is $109.88 with a high price target of $625.00 and a low price target of $61.00. Learn more on GILD's analyst rating history

Do Wall Street analysts like Gilead Sciences more than its competitors?

Analysts like Gilead Sciences stock less than the stock of other Medical companies. The consensus rating score for Gilead Sciences is 2.59 while the average consensus rating score for medical companies is 2.73. Learn more on how GILD compares to other companies

Do MarketBeat users like Gilead Sciences more than its competitors?

MarketBeat users like Gilead Sciences stock more than the stock of other Medical companies. 79.27% of MarketBeat users gave Gilead Sciences an outperform vote while medical companies recieve an average of 67.17% outperform votes by MarketBeat users.

Does Gilead Sciences's stock price have much upside?

According to analysts, Gilead Sciences's stock has a predicted upside of 71.09% based on their 12-month price targets.

What analysts cover Gilead Sciences?

Gilead Sciences has been rated by BMO Capital Markets, Morgan Stanley, Oppenheimer, Royal Bank of Canada, and SVB Leerink in the past 90 days.

This page was last updated on 9/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.